Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism.
Aerobic glycolysis
Age
Aggressive metastatic disease
Anticancer effect
Biomarker patterns
Cancer
Carcinogenesis
Cell metabolism
Chemoresistance
Co-morbidities
Disease manifestation
FDG-PET
Flavonoids
Glucose intake
Glucose metabolism
Glycolysis
Glycolytic inhibitors
HIF-1
Individual outcome
Individualised patient profiles
Ischemic lesions
Liquid biopsy
Liver malignancy
Magnetic resonance spectroscopy
Malignancy
Metabolic reprogramming
Microcirculation
Modifiable risk factors
Multi-omics
Oxidative phosphorylation
PET-CT
Palliative medicine
Patient stratification
Pleiotropic activity
Polyphenols
Positron emission tomography
Predictive preventive personalised medicine (PPPM / 3PM)
Pregnancy
Prognosis
Prognostic markers
Proliferation
Prostate cancer
Radioresistance
Risk assessment
Systemic hypoxia
Treatment algorithms
Triple-negative breast cancer
Tumour imaging
Warburg phenotype
Journal
The EPMA journal
ISSN: 1878-5077
Titre abrégé: EPMA J
Pays: Switzerland
ID NLM: 101517307
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
16
06
2020
accepted:
30
06
2020
entrez:
27
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
The Warburg effect is characterised by increased glucose uptake and lactate secretion in cancer cells resulting from metabolic transformation in tumour tissue. The corresponding molecular pathways switch from oxidative phosphorylation to aerobic glycolysis, due to changes in glucose degradation mechanisms known as the 'Warburg reprogramming' of cancer cells. Key glycolytic enzymes, glucose transporters and transcription factors involved in the Warburg transformation are frequently dysregulated during carcinogenesis considered as promising diagnostic and prognostic markers as well as treatment targets. Flavonoids are molecules with pleiotropic activities. The metabolism-regulating anticancer effects of flavonoids are broadly demonstrated in preclinical studies. Flavonoids modulate key pathways involved in the Warburg phenotype including but not limited to PKM2, HK2, GLUT1 and HIF-1. The corresponding molecular mechanisms and clinical relevance of 'anti-Warburg' effects of flavonoids are discussed in this review article. The most prominent examples are provided for the potential application of targeted 'anti-Warburg' measures in cancer management. Individualised profiling and patient stratification are presented as powerful tools for implementing targeted 'anti-Warburg' measures in the context of predictive, preventive and personalised medicine.
Identifiants
pubmed: 32843908
doi: 10.1007/s13167-020-00217-y
pii: 217
pmc: PMC7429635
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
377-398Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Oncol Rep. 2018 Nov;40(5):2788-2797
pubmed: 30132561
Food Funct. 2018 Nov 14;9(11):5682-5696
pubmed: 30310905
Biochem Soc Trans. 2016 Oct 15;44(5):1499-1505
pubmed: 27911732
EPMA J. 2019 Feb 20;10(1):81-99
pubmed: 30984317
Front Mol Biosci. 2019 Jan 22;5:120
pubmed: 30723719
Prostate. 2010 Sep 15;70(13):1388-94
pubmed: 20687211
Front Biosci (Elite Ed). 2017 Jan 1;9(1):67-75
pubmed: 27814590
Oncol Rep. 2013 Dec;30(6):2983-91
pubmed: 24064966
Annu Rev Physiol. 2020 Feb 10;82:103-126
pubmed: 31730395
Cancer Cell Int. 2013 Sep 03;13(1):89
pubmed: 24004445
Am J Hypertens. 2018 Jan 12;31(2):240-246
pubmed: 29140431
Int J Mol Sci. 2019 May 16;20(10):
pubmed: 31100782
J Immunol. 2008 Jun 1;180(11):7175-83
pubmed: 18490716
Cancer Cell. 2018 Mar 12;33(3):368-385.e7
pubmed: 29455928
Evid Based Complement Alternat Med. 2012;2012:873175
pubmed: 22844340
Clin Cancer Res. 2018 Nov 1;24(21):5206-5218
pubmed: 29884743
Sci Rep. 2018 Sep 28;8(1):14517
pubmed: 30266938
Sci Transl Med. 2011 Aug 3;3(94):94ra70
pubmed: 21813754
Biomed Pharmacother. 2017 Sep;93:1285-1291
pubmed: 28747003
Thorac Cancer. 2015 Jan;6(1):17-24
pubmed: 26273330
Amino Acids. 2018 Apr;50(3-4):383-395
pubmed: 29249020
J Nucl Med. 2013 Dec;54(12):2161-7
pubmed: 24221993
Asian J Androl. 2017 Mar-Apr;19(2):238-243
pubmed: 26780868
Infect Agent Cancer. 2020 Jan 10;15:2
pubmed: 31938038
Mol Carcinog. 2019 Jul;58(7):1194-1207
pubmed: 30854739
Oncol Rep. 2015 Jan;33(1):457-63
pubmed: 25333894
EPMA J. 2018 Feb 08;9(1):1-13
pubmed: 29515683
FEBS Lett. 2014 Aug 19;588(16):2685-92
pubmed: 24747424
Mol Med Rep. 2016 Aug;14(2):1332-8
pubmed: 27315591
Mol Cell Biol. 2017 Nov 28;37(24):
pubmed: 28993478
Genes Dis. 2017 Feb 14;4(1):25-27
pubmed: 30258905
Cancers (Basel). 2018 Dec 28;11(1):
pubmed: 30597838
Nat Rev Endocrinol. 2019 Mar;15(3):139-154
pubmed: 30459447
Nutr Cancer. 2015;67(3):504-13
pubmed: 25719685
J Agric Food Chem. 2017 Jul 26;65(29):5961-5972
pubmed: 28654261
Cell Death Dis. 2015 Apr 09;6:e1714
pubmed: 25855962
J Enzyme Inhib Med Chem. 2016;31(2):314-7
pubmed: 25798688
Mol Med Rep. 2018 Oct;18(4):4030-4036
pubmed: 30132572
Cell Biosci. 2017 Nov 13;7:62
pubmed: 29158891
Arch Pharm Res. 2019 Oct;42(10):833-847
pubmed: 31473944
Crit Rev Food Sci Nutr. 2016 Jul 29;56 Suppl 1:S4-S28
pubmed: 26463658
Front Pharmacol. 2018 May 22;9:530
pubmed: 29872398
Semin Cancer Biol. 2009 Feb;19(1):4-11
pubmed: 19101633
Cancers (Basel). 2019 Dec 30;12(1):
pubmed: 31905960
Onco Targets Ther. 2018 Jul 03;11:3793-3803
pubmed: 30013360
Nutrition. 2015 Apr;31(4):560-9
pubmed: 25770318
Mol Cancer. 2019 Feb 19;18(1):26
pubmed: 30782187
Ann Pharmacother. 2015 Apr;49(4):469-76
pubmed: 25573268
J Glob Oncol. 2019 Nov;5:1-13
pubmed: 31834832
EPMA J. 2016 Oct 25;7:23
pubmed: 27800037
Oncogene. 2011 Oct 20;30(42):4297-306
pubmed: 21516121
Clin Exp Metastasis. 2016 Dec;33(8):743-755
pubmed: 27541751
Arch Oral Biol. 2018 Dec;96:52-57
pubmed: 30179745
Antioxidants (Basel). 2018 Dec 10;7(12):
pubmed: 30544686
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
J Exp Clin Cancer Res. 2019 May 23;38(1):218
pubmed: 31122265
Free Radic Biol Med. 2020 Jan;146:119-129
pubmed: 31669347
FEBS J. 2015 Oct;282(20):3892-8
pubmed: 26255648
Cell Metab. 2016 Apr 12;23(4):649-62
pubmed: 27076078
Cancers (Basel). 2019 Jun 12;11(6):
pubmed: 31212816
Eur J Clin Invest. 2013 Aug;43(8):855-65
pubmed: 23617881
Metabolites. 2016 Oct 03;6(4):
pubmed: 27706102
EPMA J. 2019 Mar 2;10(1):73-79
pubmed: 30984316
Exp Cell Res. 2013 Jul 15;319(12):1784-1795
pubmed: 23664836
Oncotarget. 2017 Apr 25;8(17):28226-28236
pubmed: 28415668
Aging Dis. 2017 Oct 1;8(5):662-676
pubmed: 28966808
Exp Ther Med. 2016 Apr;11(4):1243-1248
pubmed: 27073430
Int J Mol Sci. 2017 Dec 22;19(1):
pubmed: 29271940
Biochem Pharmacol. 2017 Feb 1;125:12-25
pubmed: 27818240
PLoS One. 2015 Jul 09;10(7):e0132285
pubmed: 26158266
Cells. 2019 Jan 26;8(2):
pubmed: 30691108
Molecules. 2019 May 24;24(10):
pubmed: 31137633
Molecules. 2020 Mar 19;25(6):
pubmed: 32204409
Life Sci. 2019 Apr 15;223:38-46
pubmed: 30862570
Cells. 2019 Jan 31;8(2):
pubmed: 30708988
Curr Urol. 2017 Jan;9(4):212-215
pubmed: 28413383
EPMA J. 2018 Feb 22;9(1):15-20
pubmed: 29515684
J Hematol Oncol. 2018 Dec 14;11(1):139
pubmed: 30547809
J Transl Med. 2017 Jul 19;15(1):158
pubmed: 28724379
EPMA J. 2018 Aug 17;9(3):271-285
pubmed: 30174763
Exerc Sport Sci Rev. 2018 Jan;46(1):48-55
pubmed: 28816705
J Biol Chem. 2011 Dec 2;286(48):41600-41615
pubmed: 21862591
Biomark Cancer. 2016 Sep 20;8(Suppl 2):61-9
pubmed: 27679534
PLoS One. 2016 Mar 09;11(3):e0151134
pubmed: 26960146
Drug Resist Updat. 2018 May;38:1-11
pubmed: 29857814
Mol Cancer. 2013 Dec 03;12:152
pubmed: 24298908
Ned Tijdschr Geneeskd. 2016;160:A9489
pubmed: 26813013
Cell Commun Signal. 2019 Nov 21;17(1):154
pubmed: 31752925
Phytochemistry. 2015 Aug;116:262-268
pubmed: 25890391
Cancer Lett. 2018 Jan 28;413:11-22
pubmed: 29097249
J Cell Mol Med. 2017 Nov;21(11):2837-2851
pubmed: 28524540
Front Nutr. 2018 Apr 16;5:25
pubmed: 29713632
Sci Transl Med. 2013 Aug 14;5(198):198ra108
pubmed: 23946197
Clin Epigenetics. 2015 Jul 10;7:64
pubmed: 26161152
Onco Targets Ther. 2019 Nov 01;12:9053-9058
pubmed: 31802912
Oncotarget. 2017 Apr 4;8(14):22305-22306
pubmed: 28423591
J Exp Clin Cancer Res. 2019 May 17;38(1):204
pubmed: 31101057
Oncotarget. 2014 Jul 30;5(14):5535-46
pubmed: 25114038
Pancreas. 2008 Nov;37(4):426-31
pubmed: 18953257
EPMA J. 2017 Apr 10;8(2):129-140
pubmed: 28824738
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2729-2736
pubmed: 31284780
Anticancer Agents Med Chem. 2017;17(2):164-170
pubmed: 27804847
Br J Cancer. 2008 Oct 7;99(7):989-94
pubmed: 18766181
Int Immunol. 2011 Jan;23(1):29-41
pubmed: 21131367
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3747-3754
pubmed: 30046816
Med Sci Sports Exerc. 2019 Apr;51(4):773-781
pubmed: 30489496
Transl Oncol. 2018 Jun;11(3):628-632
pubmed: 29574327
Curr Top Med Chem. 2018;18(6):494-504
pubmed: 29788892
Cell Cycle. 2018;17(4):428-438
pubmed: 29468929
J Mol Med (Berl). 2011 Mar;89(3):213-20
pubmed: 21301796
J Oral Maxillofac Surg. 2016 Apr;74(4):844-50
pubmed: 26541225
Med Oncol. 2015 Jul;32(7):187
pubmed: 26021472
Cancer. 2020 Jan 1;126(1):46-57
pubmed: 31553489
Cancer Res. 2018 Jul 1;78(13):3432-3444
pubmed: 29691252
Asian Pac J Cancer Prev. ;18(4):1127-1131
pubmed: 28547952
Nat Rev Cancer. 2011 Feb;11(2):85-95
pubmed: 21258394
EMBO Rep. 2016 Aug;17(8):1204-20
pubmed: 27317567
Int J Biol Sci. 2019 Sep 7;15(11):2497-2508
pubmed: 31595166
Curr Opin Oncol. 2009 Nov;21(6):531-6
pubmed: 19587591
PLoS One. 2015 May 26;10(5):e0127464
pubmed: 26011160
J Nucl Med. 2016 Oct;57(Suppl 3):25S-29S
pubmed: 27694167
Onco Targets Ther. 2016 Dec 22;10:137-144
pubmed: 28053547
Molecules. 2019 Jun 19;24(12):
pubmed: 31248102
Evid Based Complement Alternat Med. 2014;2014:180981
pubmed: 24795764
Rocz Panstw Zakl Hig. 2014;65(2):79-85
pubmed: 25272572
Curr Pharm Des. 2005;11(19):2405-27
pubmed: 16026296
Mol Biol Rep. 2015 Apr;42(4):825-34
pubmed: 25253100
Am J Cancer Res. 2019 Aug 01;9(8):1517-1535
pubmed: 31497340
EPMA J. 2015 Apr 15;6(1):9
pubmed: 25908947
Cancer Imaging. 2016 Jun 08;16(1):14
pubmed: 27277843
EPMA J. 2014 Jul 08;5(1):11
pubmed: 25075228
Oncol Rep. 2015 Dec;34(6):2821-6
pubmed: 26398719
Cell Cycle. 2012 Mar 15;11(6):1108-17
pubmed: 22313602
EPMA J. 2017 Mar 3;8(1):23-33
pubmed: 28620441
EPMA J. 2017 Mar 8;8(1):17-22
pubmed: 28620440
Anticancer Agents Med Chem. 2014 Jun;14(5):771-6
pubmed: 24738957
Endocrinology. 2014 Sep;155(9):3238-50
pubmed: 24932809
Antioxidants (Basel). 2019 May 18;8(5):
pubmed: 31109072
J Bioenerg Biomembr. 2015 Aug;47(4):319-29
pubmed: 26054380
Life Sci. 2018 Sep 1;208:123-130
pubmed: 30025823
Mediators Inflamm. 2018 Dec 30;2018:1218297
pubmed: 30692870
Biomol Ther (Seoul). 2018 Jan 1;26(1):81-92
pubmed: 29212309
J Med Food. 2010 Aug;13(4):808-14
pubmed: 20553191
Biochim Biophys Acta Bioenerg. 2017 Aug;1858(8):556-572
pubmed: 28167100
Curr Opin Oncol. 2012 Nov;24(6):650-4
pubmed: 22913968
Int J Mol Sci. 2018 Mar 23;19(4):
pubmed: 29570697
J Biol Chem. 2009 Feb 27;284(9):5859-68
pubmed: 19091749
Semin Nephrol. 2019 Jul;39(4):380-393
pubmed: 31300093
Oncol Lett. 2016 Mar;11(3):1980-1986
pubmed: 26998110
Oncotarget. 2018 Jan 8;9(28):20089-20102
pubmed: 29732005
Eur J Nutr. 2016 Apr;55(3):955-65
pubmed: 25930965
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5
pubmed: 10984506
Oncotarget. 2016 Apr 5;7(14):18940-52
pubmed: 26980745
Oncol Rep. 2019 Apr;41(4):2321-2328
pubmed: 30720119
Cell Biosci. 2017 Oct 5;7:50
pubmed: 29034071
EPMA J. 2020 May 29;11(2):261-287
pubmed: 32547652
Mol Carcinog. 2016 Sep;55(9):1317-28
pubmed: 26258875
Int J Mol Sci. 2019 Oct 09;20(20):
pubmed: 31600949
Cancer Prev Res (Phila). 2015 Dec;8(12):1184-1191
pubmed: 26511489
Mol Ther Nucleic Acids. 2016 Aug 30;5(8):e357
pubmed: 27574783
Int J Mol Sci. 2019 Mar 09;20(5):
pubmed: 30857300
Radiother Oncol. 2006 Jun;79(3):270-7
pubmed: 16797755
J BUON. 2019 May-Jun;24(3):990-996
pubmed: 31424652
PLoS One. 2016 Oct 12;11(10):e0164244
pubmed: 27732654
Int J Mol Sci. 2018 Sep 25;19(10):
pubmed: 30257458
World Rev Nutr Diet. 2013;106:83-9
pubmed: 23428685
Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):255-73
pubmed: 24142805
Am J Transl Res. 2018 Jun 15;10(6):1793-1801
pubmed: 30018720
Biomed Rep. 2018 Jan;8(1):3-10
pubmed: 29399334
Future Oncol. 2019 Oct;15(28):3189-3196
pubmed: 31512497
Clin Chim Acta. 2003 Jan;327(1-2):129-37
pubmed: 12482628
Am J Transl Res. 2019 Jun 15;11(6):3341-3352
pubmed: 31312348
Cell Death Differ. 2020 May;27(5):1660-1676
pubmed: 31685978
J Clin Invest. 2013 Sep;123(9):3664-71
pubmed: 23999440
Nat Rev Mol Cell Biol. 2018 Feb;19(2):121-135
pubmed: 28974774
Anticancer Res. 2015 Nov;35(11):5889-99
pubmed: 26504012
Cancer. 2004 Oct 1;101(7):1569-74
pubmed: 15468186
Sci Rep. 2016 Apr 15;6:24324
pubmed: 27079271
Semin Nephrol. 2018 Mar;38(2):111-120
pubmed: 29602394
J Agric Food Chem. 2017 Sep 20;65(37):8136-8144
pubmed: 28829588
J Cell Biochem. 2018 Nov;119(10):8501-8510
pubmed: 30015359
Front Cell Dev Biol. 2018 Jul 24;6:79
pubmed: 30087897
Nature. 2019 Oct;574(7779):575-580
pubmed: 31645732
Cancers (Basel). 2019 Nov 14;11(11):
pubmed: 31739537
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2037-42
pubmed: 20133848
Semin Oncol. 2011 Feb;38(1):55-69
pubmed: 21362516
Cancer Metastasis Rev. 2019 Jun;38(1-2):5-15
pubmed: 30707328
Int J Mol Sci. 2018 Mar 23;19(4):
pubmed: 29570635
EPMA J. 2018 Feb 21;9(1):77-102
pubmed: 29515689
EPMA J. 2018 Aug 02;9(3):307-317
pubmed: 30174766
Front Pharmacol. 2020 Jan 28;10:1614
pubmed: 32116665
Geburtshilfe Frauenheilkd. 2017 Oct;77(10):1095-1103
pubmed: 29093603
F1000Prime Rep. 2015 Apr 02;7:41
pubmed: 26097714
Cell Biochem Funct. 2013 Jul;31(5):374-9
pubmed: 23042260
Oncol Lett. 2019 Jun;17(6):5441-5446
pubmed: 31186763
Int J Mol Sci. 2019 Apr 09;20(7):
pubmed: 30970626
Amino Acids. 2017 Feb;49(2):273-281
pubmed: 27812894
Bioengineered. 2019 Dec;10(1):374-382
pubmed: 31431131
BMC Complement Altern Med. 2018 Dec 4;18(1):317
pubmed: 30514289
Int J Radiat Biol. 2019 Jul;95(7):912-919
pubmed: 30822194
Int J Mol Sci. 2019 Jul 09;20(13):
pubmed: 31324056
J Cancer. 2017 Sep 20;8(17):3430-3440
pubmed: 29151926
Oncotarget. 2016 Jun 1;8(34):56081-56094
pubmed: 28915575
Cell Physiol Biochem. 2018;45(6):2548-2559
pubmed: 29558748
Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):7726-7734
pubmed: 30536316
EPMA J. 2010 Mar;1(1):130-7
pubmed: 23199047
Molecules. 2019 Oct 16;24(20):
pubmed: 31623144
Oncotarget. 2017 May 9;8(19):32332-32344
pubmed: 28415659
EMBO Rep. 2016 Dec;17(12):1721-1730
pubmed: 27856534
FEBS J. 2018 Aug;285(16):2926-2943
pubmed: 29893496
EPMA J. 2017 May 2;8(2):141-157
pubmed: 28725292
J Cell Biochem. 2011 Mar;112(3):849-59
pubmed: 21328458
BMC Cancer. 2012 Jun 12;12:232
pubmed: 22691140
Proteomics. 2008 Jan;8(1):45-61
pubmed: 18095365
Clin Transl Oncol. 2020 May;22(5):631-646
pubmed: 31359335
Cancer Sci. 2018 Aug;109(8):2423-2434
pubmed: 29869834
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11440-11445
pubmed: 29073069
Methods Enzymol. 2014;542:1-23
pubmed: 24862258
Cancers (Basel). 2019 Oct 30;11(11):
pubmed: 31671612
Oncol Lett. 2018 Jan;15(1):908-916
pubmed: 29422966
Front Endocrinol (Lausanne). 2018 Apr 12;9:129
pubmed: 29706933